# Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned

> **NCT01495663** · PHASE1 · COMPLETED · sponsor: **Cellectar Biosciences, Inc.** · enrollment: 12 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** I-131-CLR1404

## Key facts

- **NCT ID:** NCT01495663
- **Lead sponsor:** Cellectar Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2013-11
- **Final completion:** 2014-01
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2015-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01495663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01495663, "Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01495663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*